{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-26-001020","form_type":"8-K","ticker":"SBEV","cik":"0001553788","company_name":"SPLASH BEVERAGE GROUP, INC.","filed_at":"2026-08-05T12:35:42+00:00","discovered_at":"2026-08-05T12:40:00.741983+00:00","generated_at":"2026-08-05T12:40:08.972402+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Splash Beverage Group partners with Lupvindol Biosciences to advance CannEpil through FDA veterinary pathway","bullets":["Collaboration targets companion-animal oncology and chronic pain management; canine applications are initial focus.","Lupvindol CEO Hunter Land, Ph.D., led development of first FDA-approved plant-derived cannabinoid medicine Epidiolex.","Global veterinary pain-management market valued at $2.6B in 2024, projected to reach $3.8B by 2030.","Splash retains ownership of data, IP, and commercialization rights; provides milestone-based funding.","Program aims for FDA Conditional Approval under Section 571 of FD&C Act; no assurance of approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-001020","json":"https://secwatch.observer/filing/0001731122-26-001020.json","markdown":"https://secwatch.observer/filing/0001731122-26-001020.md","text":"https://secwatch.observer/filing/0001731122-26-001020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226001020/0001731122-26-001020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226001020/e7828_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T12:40:08.972402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}